Strategic acquisitions IBA Dosimetry’s acquisition of Radcal Corporation expands its dosimetry offerings and strengthens its US footprint, signaling potential cross-sell opportunities to Radcal customers and a broader installed base for QA solutions and imaging markers.

Integrated QA platform The launch and ongoing evolution of myQA iON and enhanced myQA Machines software indicate a strong move toward integrated QA platforms that can consolidate multiple QA workflows, creating a pathway to upsell advanced software modules and service contracts to existing users.

Global presence With headquarters in Germany and subsidiaries in the US and China, IBA Dosimetry serves a diverse, global market, presenting opportunities to tailor regional solutions, expand channel partnerships, and target multinational hospitals and radiotherapy centers.

End-to-end solutions Offering a full range of instruments and software for QA and calibration positions the company to pursue multi-product deals with medical physicists and radiologists seeking comprehensive dosimetry and imaging solutions, including potential bundles with Radcal assets.

Industry leadership signals Positioned as the world’s leading dosimetry solution provider in installed systems, IBA Dosimetry can leverage its market leadership in messaging to win deals with mid-to-large volume institutions seeking proven reliability, while targeting competitors' customers looking for enhanced support and integration.